Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Adattiva alla risposta a epcoritamab in prima recidiva: studio per valutare l'efficacia di eptoritamab in pazienti con linfoma a cellule B di grandi dimensioni/refrattari (REPIFIR)

Adattiva alla risposta a Epcoritamab in prima recidiva: uno studio multicentrico di fase II, adattativo, etichetta aperta, etichetta aperta per valutare l'efficacia di ePoritamab in pazienti con linfoma a cellule B di grandi dimensioni/refrattari di grandi dimensioni

phase II, response-adaptive, open-label, multicenter study aiming to include 80 patients in 78 months. Patients will receive 3 cycles of epcoritamab monotherapy and, since cycle 4, they can continue with epcoritamab monotherapy until cycle 12 or change to combination therapy (epcoritamab + tafasitamab + lenalidomide) until cycle 15. Patients will be followed up to 5 years.

Panoramica dello studio

Descrizione dettagliata

Epcoritamab is a full-length bispecific IgG1 antibody directed against two proteins, CD3 on the T lymphocyte and CD20 on the lymphoma cell. This antibody redirects and activates T cells, generating an immune synapse that eventually eliminates malignant cells expressing CD20.

Previous studies have demonstrated that Epcoritamab has potent antitumor activity as a monotherapy agent, with a favorable and manageable safety profile.

Since its efficacy is so favorable it is reasonable to think that it could be an excellent option for first-relapse patients. However, to date, there is no data on this therapy's usefulness as second-line treatment. Therefore we intend to evaluate the efficacy of Epcoritamab as a treatment option for patients with first-relapse LBCL.

The purpose of this study is to determine the efficacy of Epcoritamab as second line treatment for LBCL patients. On the basis of the clinical experience, it is hypothesized that Epcoritamab would provide a better complete response rate (CRR) in comparison to Platinum-based immunochemotherapy (CRR=25%), Polatuzumab-Bendamustin Rituximab (CRR=40%) and Tafasitamab-Lenalidomide (CRR=43%).

Tipo di studio

Interventistico

Iscrizione (Stimato)

80

Fase

  • Fase 2

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Backup dei contatti dello studio

Luoghi di studio

    • Andalusia
      • Seville, Andalusia, Spagna, 41013
        • Reclutamento
        • Hospital Universitario Virgen del Rocío
        • Contatto:
    • Aragon
      • Zaragoza, Aragon, Spagna, 50009
        • Reclutamento
        • Hospital Universitario Miguel Servet
        • Contatto:
    • Balearic Islands
      • Palma de Mallorca, Balearic Islands, Spagna, 07120
        • Reclutamento
        • Hospital Universitario Son Espases
        • Contatto:
    • Castille and León
      • Burgos, Castille and León, Spagna, 09006
        • Reclutamento
        • Hospital Universitario de Burgos
        • Contatto:
      • Salamanca, Castille and León, Spagna, 37007
        • Reclutamento
        • Hospital Universitario de Salamanca
        • Contatto:
          • Alejandro Martín García-Sancho, MD
          • Numero di telefono: +34 923 291 100
          • Email: amartingar@usal.es
    • Catalonia
      • Badalona, Catalonia, Spagna, 08916
        • Reclutamento
        • ICO Badalona
        • Contatto:
      • Barcelona, Catalonia, Spagna, 08035
        • Reclutamento
        • Hospital Universitari Vall d'Hebrón
        • Contatto:
    • Extremadura
      • Cáceres, Extremadura, Spagna, 10003
        • Reclutamento
        • Hospital San Pedro de Alcántara
        • Contatto:
    • Madrid
      • Madrid, Madrid, Spagna, 28041
        • Reclutamento
        • Hospital Universitario 12 de Octubre
        • Contatto:
      • Madrid, Madrid, Spagna, 28007
        • Reclutamento
        • Hospital General Universitario Gregorio Marañón
        • Contatto:
      • Madrid, Madrid, Spagna, 28031
      • Madrid, Madrid, Spagna, 28040
        • Reclutamento
        • Hospital Universitario Fundación Jiménez Díaz
        • Contatto:
    • Murcia
      • El Palmar, Murcia, Spagna, 30120
        • Reclutamento
        • Hospital Virgen de la Arrixaca
        • Contatto:
    • Málaga
      • Marbella, Málaga, Spagna, 29603
        • Reclutamento
        • Hospital Universitario Costa del Sol
        • Contatto:
    • Principality of Asturias
      • Oviedo, Principality of Asturias, Spagna, 33011
        • Reclutamento
        • Hospital Universitario Central de Asturias
        • Contatto:
    • Tenerife
      • San Cristóbal de La Laguna, Tenerife, Spagna, 38320
    • Valencia
      • Valencia, Valencia, Spagna, 46017
        • Reclutamento
        • Hospital Universitario Dr. Peset
        • Contatto:
      • Valencia, Valencia, Spagna, 46024
        • Reclutamento
        • Hospital Universitario y Politécnico La Fe
        • Contatto:
    • Vizcaya
      • Bilbao, Vizcaya, Spagna, 48013
        • Reclutamento
        • Hospital Universitario de Basurto
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  1. Written informed consent must be obtained before any study-specific assessment is performed.

  2. Age >18 years

  3. Patients with Relapse/Refractory histologically confirmed LBCL, including, Diffuse Large B Cell Lymphoma (DLBCL); Primary Mediastinal Large B Cell Lymphoma (PMBCL), High-grade B-cell lymphoma (HGBCL); and grade 3B Follicular Lymphoma.

    Relapsed disease is defined as complete remission to first line therapy followed by a recurrence of the disease after a minimum of 6 months of completion of first-line therapy. A biopsy at the time of relapse is recommended but not mandatory.

    Refractory disease is defined as no objective response to first line therapy (biopsy not mandatory if diagnostic sample available). Four groups of patients are eligible:

    • PD as best response to first line therapy.
    • SD as best response after at least 4 cycles of first line therapy.
    • PR as best response after at least 6 cycles of first line therapy.
    • CR and disease recurrence within < 6 months from the completion of first-line therapy.
  4. Patients must have received adequate first-line therapy including at a minimum: an anti-CD20 monoclonal antibody (rituximab or obinutuzumab), and CHOP (cyclophosphamide, hydroxydaunomycin, oncovin, and prednisone) or CHOP-like chemotherapy.

  5. At the investigator's discretion, the patient should not be a candidate for 1st relapse CAR-T therapy or unwilling to receive CAR-T therapy.

  6. Patients must be autologous stem cell transplantation (ASCT)-ineligible: Age ≥65 and/or HTC-CI ≥3 or or unwilling to receive transplant.

  7. PET positive disease.

  8. Performance status according to Eastern Cooperative Oncology Group (ECOG) 0 to 2.

  9. Patients meeting with the following hematology values:

    • Hemoglobin ≥8 g/dl (transfusion support permitted but not within 7 days of screening lab collection)
    • Absolute neutrophil count (ANC) ≥ 1/109/L (growth factor support allowed in case of bone marrow involvement).
    • Absolute lymphocyte count ≥ 0.1/109/L,
    • Platelet count ≥ 70/109/L (unless secondary to bone marrow involvement, OR ≥50x/109/L if documented bone marrow involvement). Platelet transfusions permitted but not within 7 days of screening lab collection.
  10. Female patients of child-bearing potential must have a negative urine or serum pregnancy test at screening and agree to use highly effective methods of contraception (e.g., established use of oral, injected or implanted combined (estradiol and progesterone containing) hormonal contraception; placement of an intrauterine device (IUD) or intrauterine system (IUS) upon enrollment according to the recommendations provided by Clinical Trial Facilitation Group (CTFG), during the treatment period and for 4 months after the last dose of study medication. Moreover, the patient must agree to ongoing pregnancy testing during the course of the study, and after study therapy has ended. This applies even if the patient practices complete and continued sexual abstinence.

    Women not of childbearing potential are defined as: premenarchal; postmenopausal (greater than 50 years of age with amenorrhea for at least 12 months or any age with amenorrhea for at least 6 months and a serum follicle stimulating hormone (FSH) level greater than 40 IU per L or milli-International unit (mIU) per mL); permanently sterilized (e.g., bilateral tubal occlusion [which includes tubal ligation procedures as consistent with local regulations], hysterectomy, bilateral salpingectomy, bilateral oophorectomy); or otherwise be incapable of pregnancy.

  11. Male patients must use a reliable method of contraception (if sexually active with a female of child-bearing potential) upon enrollment according to the recommendations provided by CTFG, during the treatment period, and for 4 months following the last dose of investigational drug or agreement to remain abstinent. Agreement to refrain from donating blood or sperm during the study participation and for 4 months after the last dose of study medication.

  12. Women must agree not to donate blood or oocytes during the course of the study and for 4 months after the last dose of study medication. Restrictions concerning blood donation apply as well to females who are not of childbearing potential. Men must also not donate sperm during the trial and for 4 months after receiving the last dose of study drug.

  13. Females of childbearing potential must refrain from breastfeeding during the course of the study and for 4 months after the last dose of study medication.

  14. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.

  15. Not included in other clinical trial or treated with an experimental drug.

Exclusion Criteria:

  1. Patients who received more than one prior line of systemic therapy

  2. Patients with detectable Central Nervous System (CNS) lymphoma

  3. Significant organ function impairment:

    • creatinine clearance calculated by Cockcroft-Gault ≤ 45 ml/min
    • direct bilirubin level < 2 x ULN (except in patients with Gilbert's syndrome),
    • alanine transaminase (ALT) and aspartate aminotransferase (AST) >3 × ULN or >5 × ULN in cases of documented liver involvement.
    • clinically relevant pleural effusion,
    • left ventricular ejection fraction (LVEF) ≤ 45%
  4. Serious accompanying disorder leading to impaired organ function causing significant clinical problems and reduced life expectancy of less than 3 months.

  5. Have a history of deep venous thrombosis/embolism, threatening thromboembolism or known thrombophilia or are at a high risk for a thromboembolic event in the opinion of the investigator and who are not willing/able to take venous thromboembolic event prophylaxis during the entire treatment period

  6. Known clinically significant cardiac disease, including:

    • Onset of unstable angina pectoris within 6 months of signing the patient informed consent form.
    • Acute myocardial infarction within 6 months of signing the patient informed consent form.
    • Congestive heart failure (grade III or IV as classified by the New York Heart Association.
    • Left ventricular ejection fraction ≤45%.
  7. Known past or current malignancy other than inclusion diagnosis, except for: Cervical carcinoma of Stage 1B or less; Non-invasive basal cell or squamous cell skin carcinoma; Non-invasive, superficial bladder cancer; Localized low grade prostate cancer (up to Gleason score 6); DCIS of the breast; Other malignancy that has been treated with curative intent and has remained in remission for 3 years.

  8. Previous ASCT.

  9. Prior anti-CD3 and CD20 bispecific antibodies therapy or prior treatment with tafasitamab.

  10. Presence of severe infection that is uncontrolled or requiring IV antimicrobials for management.

  11. History of HIV infection or acute or chronic active hepatitis B or C infection.

    • Individuals with positive HIV serology may be included if negative viral load and CD4 >200/mm3. For being included, patients should have controlled disease and been on treatment for at least 1 year
    • Individuals with history of hepatitis infection with positive antibodies (anti-HB and anti-HV) might be included if negative viral load (negative hepatitis B PCR). Patients who are HBcAb positive must receive HBV prophylaxis while on treatment. Patients with positive HbsAg are excluded. Patients who are hepatitis B PCR positive will be excluded. Patients who are hepatitis C RNA positive will be excluded.
  12. Females who are pregnant or breastfeeding.

  13. Richter's transformation or prior chronic lymphocytic leukemia (CLL).

  14. Treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational agent for the purposes of treating cancer within 4 weeks prior to Cycle 1 Day 1.

  15. Recent major surgery (within 4 weeks before the start of Cycle 1 Day 1) other than for diagnosis.

  16. Vaccination with a live vaccine or COVID-19 vaccination within 4 weeks prior to treatment.

  17. History of hypersensitivity to any of the study drugs or their ingredients or to drugs with similar structure. History of severe allergic or anaphylactic reactions to human, humanized, chimeric, or murine monoclonal antibodies.

  18. Close affiliation with the investigator (e.g. a close relative) or persons working at the study site.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Non randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: EPCO monotherapy

Epcoritamab in monotherapy will be administred until cycle 12.

Patients will receive 12 cycles of Epcoritamab monotherapy.

Sperimentale: Combination therapy

3 cycles of Epcoritamab in monotherapy will be administred and then Epcoritamab will be administred with Tafasitamab and Lenalidomide from cycle 4 until cycle 15.

Patients will receive 3 cycles of Epcoritamab monotherapy and then 12 cycles of Epcoritamab, Tafasitamab and Lenalidomide.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Efficacy of Epcoritamab monotherapy
Lasso di tempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.

The efficacy of Epcoritamab monotherapy will be centrally evaluated by the best CRR at any moment since initiation. The CRR will be assessed by PET-CT according to Lugano Classification and is defined as the proportion of patients who achieve a best response of complete response (CR) at any moment since initiation of Epcoritamab first administration.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Efficacy of Epcoritamab monotherapy after 3 cycles
Lasso di tempo: At the end of cycle 3 (each cycle is 28 days)

The efficacy of Epcoritamab monotherapy will be centrally evaluated by the best CRR, defined as the proportion of patients who achieve a best response of CR after 3 cycles of Epcoritamab administration.

At the end of cycle 3 (each cycle is 28 days)
Efficacy of Epcoritamab monotherapy and combination therapy by CRR
Lasso di tempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.

The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per CRR (locally evaluated for Epcoritamab monotherapy; local and central evaluation for combination therapy).

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
Evaluation of MRD
Lasso di tempo: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).

The efficacy of Epcoritamab monotherapy and combination therapy will be evaluated by MRD (positive or negative) from ctDNA samples immediately before initiation of C3, C4, C7, C10, C12, C13, C15, End of Treatment (EoT) and cycles 18/24 (epcoritamab monotherapy) or cycles 21/27 (combination therapy).

Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
Evaluation of patients with negative MRD by PFS
Lasso di tempo: At cycle 3 visit (each cycle is 28 days).

The PFS of patients with negative MRD at Visit 3 (V3) (immediately before administrating C3 of Epcoritamab monotherapy).

At cycle 3 visit (each cycle is 28 days).
Safety and tolerability
Lasso di tempo: Baseline, during all the cycles day 1 visit (each cycle is 28 days) and at EoT (28 days afert las administration of Study drug).

The safety and tolerability of Epcoritamab monotherapy and combination therapy are evaluated as follows:

  • Type, frequency, and severity of adverse events (AEs).
  • Type, frequency, and severity of Adverse events of special interest (AESIs): Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), clinical tumor lysis syndrome (CTLS) and other safety topics of interest (tumour flare reaction, prolonged cytopenia, serious infections and second primary malignancies).
  • Incidence, severity, and treatment.
Baseline, during all the cycles day 1 visit (each cycle is 28 days) and at EoT (28 days afert las administration of Study drug).
Efficacy of Epcoritamab Monotherapy and Combination therapy by ORR
Lasso di tempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days

The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per ORR at any time.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
Efficacy of Epcoritamab Monotherapy and combination therapy by DoR
Lasso di tempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days

The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per DoR at any time.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
Efficacy of Epcoritamab monotherapy and combination therapy by DoCR
Lasso di tempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days

The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per DoCR at any time.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
Efficacy of Epcoritamab monotherapy and combination therapy by EFS
Lasso di tempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days

The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per Event-free survival (EFS) at any time.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
Efficacy of Epcoritamab monotherapy and combination therapy by PFS
Lasso di tempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days

The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per PFS at any time.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
Efficacy of Epcoritamab montherapy and combination therapy by OS
Lasso di tempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days

The efficacy of Epcoritamab monotherapy and combination therapy with tafasitamab-lenalidomide will be evaluated by local investigators and central evaluation as per OS at any time.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days
Evaluation of patients with negative MRD by OS
Lasso di tempo: At cycle 3 visit (each cycle is 28 days).

The OS of patients with negative MRD at Visit 3 (V3) (immediately before administrating C3 of Epcoritamab monotherapy).

At cycle 3 visit (each cycle is 28 days).
Evaluation of patients with negative MRD by DoR
Lasso di tempo: At cycle 3 visit (each cycle is 28 days).

The DoR of patients with negative MRD at Visit 3 (V3) (immediately before administrating C3 of Epcoritamab monotherapy).

At cycle 3 visit (each cycle is 28 days).

Altre misure di risultato

Misura del risultato
Misura Descrizione
Lasso di tempo
Response of patients stopping treatment by PFS
Lasso di tempo: At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).

To compare the PFS of patients stopping therapy after 1 year of treatment (CR by PET-CT and negative MRD) with the groups of patients who continue monotherapy or receive combination.

At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).
Correlation between biomarkers and study treatment by ORR
Lasso di tempo: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).

Correlation between biomarkers and study treatment efficacy determined by ORR.

Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
Efficacy of Epcoritamab monotherapy and combination therapy in patients reintroducing treatment by DoR
Lasso di tempo: After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days).

Efficacy of Epcoritamab or Epcoritamab/Tafasitamab by DoR in patients reintroducing the study treatment with a MRD positive result.

After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days).
MRD negativity
Lasso di tempo: through study completion, an average of 5 years

Median duration of molecular response (MRD negativity).

through study completion, an average of 5 years
Correlation between tumor volume and efficacy
Lasso di tempo: Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.

Correlation between Total Metabolic Tumor Volume (centrally evaluated) and study treatment efficacy determined by PFS and OS.

Cycle 3, cycle 4, cycle 7, cycle 10, cycle 13 (for combination therapy) and EoT (28 days after last administration of investigational product) visits. Each cycle is 28 days.
ctDNA levels
Lasso di tempo: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).

Descriptive analysis of dynamic changes in ctDNA levels

Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
Correlation between lymphocyte subsets and efficacy
Lasso di tempo: Through study completion, an average of 5 years.

Correlation between lymphocyte subsets and study treatment efficacy determined by ORR, CRR, DoR, PFS and OS and safety determined by type, frequency, and severity of adverse events.

Through study completion, an average of 5 years.
Response of patients stopping treatment
Lasso di tempo: At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).

To compare the DoR of patients stopping therapy after 1 year of treatment (CR by PET-CT and negative MRD) with the groups of patients who continue monotherapy or receive combination.

At EoT visit (28 days after last administration of Study drug) for monotherapy and at C13 visit for combination therapy (each cycle is 28 days).
Correlation between biomarkers and study treatment efficacy by CRR
Lasso di tempo: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).

Correlation between biomarkers and study treatment efficacy determined by CRR.

Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
Correlation between biomarkers and study treatment efficacy DoR
Lasso di tempo: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).

Correlation between biomarkers and study treatment efficacy determined by DoR, PFS and OS.

Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
Correlation between biomarkers and study treatment efficacy by PFS
Lasso di tempo: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).

Correlation between biomarkers and study treatment efficacy determined by PFS.

Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
Correlation between biomarkers and study treatment efficacy by OS
Lasso di tempo: Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).

Correlation between biomarkers and study treatment efficacy determined by OS.

Cycles 3, 4, 7, 10, 12, 13, 15 (each cycle is 28 days), EoT (28 days after last administration of Study drug) and cycles 18 and 24 (epcoritamab monotherapy) or cycles 21 and 27 (combination therapy) visits (each cycle is 28 days).
Efficacy of Epcoritamab monotherapy and combination therapy in patients reintroducing treatment by PFS
Lasso di tempo: After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)

Efficacy of Epcoritamab or Epcoritamab/Tafasitamab by PFS in patients reintroducing the study treatment with a MRD positive result.

After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)
Efficacy of Epcoritamab monotherapy and combination therapy in patients reintroducing treatment by OS
Lasso di tempo: After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)

Efficacy of Epcoritamab or Epcoritamab/Tafasitamab by OS in patients reintroducing the study treatment with a MRD positive result.

After reintroduction of study treatment due to MRD positive result, on cycles 13, 16, 19, 22, 25, 28 visits (each cycle is 28 days)

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Investigatori

  • Investigatore principale: Mariana Bastos-Oreiro, Hospital General Universitario Gregorio Marañon
  • Investigatore principale: Pau Abrisqueta, Hospital Universitari Vall d'Hebrón

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Collegamenti utili

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 agosto 2025

Completamento primario (Stimato)

27 dicembre 2031

Completamento dello studio (Stimato)

27 dicembre 2031

Date di iscrizione allo studio

Primo inviato

10 luglio 2025

Primo inviato che soddisfa i criteri di controllo qualità

9 agosto 2025

Primo Inserito (Effettivo)

17 agosto 2025

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

29 settembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

24 settembre 2026

Ultimo verificato

1 settembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Data obtained through this study may be provided to qualified researchers with academic interest in hematology diseases. All individual data collected during the trial will be available. Data shared will be coded, with no PHI included. Study protocol, statistical analysis plan, informed consent form and clinical study report will be also available. Information will be available beginning 6 months after final publication with no end date established. Approval of the request and execution of all applicable agreements are prerequisites to the sharing of data with the requesting party. Data requests can be submitted starting 6 months after article publication. Access to trial IPD can be requested by qualified researchers and will be provided following review and approval of a research and execution of a Data Sharing Agreement (DSA). For more information or to submit a request, please contact to GELTAMO though the web page: https://www.geltamo.com/contacto

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi